GenoLens logoGenoLens

About SciLicium

Bioinformatics for scientists,
not just bioinformaticians

SciLicium started in 2020 in Rennes. The founding team was bioinformaticians, biologists, and data scientists who kept running into the same problem: the people generating biological data and the scientists trying to interpret it had almost no overlap. We built tools to close that gap.

Today we work with R&D teams in cosmetics, pharma, and biotech. OmicSkin handles transcriptomics for safety and efficacy studies. SkinMAP is a single-cell atlas of human skin. TOXsIgN covers toxicogenomics. GenoLens brings it all into one place. None of it requires an in-house bioinformatician.

The SciLicium team
2020
Founded in Rennes
30+
Projects completed
12,000+
Samples analyzed
15+
Research partners

Our Mission

Bioinformatics that works
for the scientist, not the other way around

We measure success with one question: can an R&D team go from raw omics data to results they can act on, without needing a bioinformatician on staff? If yes, we did our job. The scientific rigour has to hold up either way.

🔬

Scientific integrity

We don't cut corners on statistical methods. Every analysis follows established methodology, and we document everything.

💡

Innovation

Bioinformatics tools age fast. We stay current with the field and rebuild things when better approaches exist.

🤝

Collaboration

The best work we do comes from staying close to the scientists using our tools. We treat that feedback seriously.

📊

Data-driven

Our recommendations come from statistics, not intuition. When the data does not support a conclusion, we say so.

Our Journey

From prototype to platform

2020
Founded

SciLicium is founded in Rennes by a small team of bioinformaticians and biologists. The first client projects are in cosmetics transcriptomics.

2022
CIR certification

The French government grants SciLicium its Crédit d'Impôt Recherche certification, confirming its R&D status.

2023
OmicSkin

OmicSkin launches. A transcriptomics platform built for cosmetic safety and efficacy studies, now open to research partners.

2024
SkinMAP

SkinMAP opens to research partners. A single-cell atlas of human skin built to speed up cell type discovery.

2025-2026
GenoLens

GenoLens is in active development. An accessible visualisation and analysis platform extending our tools across the full omics pipeline.

The Team

Built by researchers, for researchers

Everyone on the team has a scientific background. Most have PhDs. They come from bioinformatics, biology, data science, and project management.

🧬
Bioinformatics

Our bioinformaticians handle transcriptomics, metagenomics, and multi-omics pipelines. Most have PhDs and active research experience.

📊
Data science & AI

Our data scientists build the statistical models and machine learning layers that take raw results and make them readable.

🔬
Molecular biology

Having biologists in the room keeps the analysis grounded. They catch things that look statistically fine but make no biological sense.

🗂️
Project management

Our project managers own timelines and client communication so the scientists can focus on the science.

We're growing the team.

See open positions

Recognition

Credentials & scientific output

🏆
Crédit d'Impôt Recherche·2022
The French government certified SciLicium as an R&D company, recognising its investment in life sciences bioinformatics.
📄
Scientific literature·15+ publications
Peer-reviewed papers in bioinformatics, genomics, and computational toxicology, published since 2020.
🗣️
International conferences·10 posters · 8 talks
10 scientific posters and 8 oral presentations at life sciences conferences across Europe.
🔬
Platform portfolio·5 platforms
Five tools in production: OmicSkin, SkinMAP, TOXsIgN, GenoLens, and a dedicated analysis service.

Get in touch

Want to know more about SciLicium?

If you're a potential customer, partner, investor, or researcher, we'd love to talk.